7 modalities · 1 complete · 6 partly written · 0 not yet written
Modalities
Kinds of medicine. For each: what stays the same as the small-molecule path and what changes downstream.
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
-
Antisense oligonucleotide (ASO)An antisense oligonucleotide (ASO) is a short, chemically armoured single strand of nucleic acid that pairs with one RNA to destroy it, block it or change how it is spliced. complete
In brief. An antisense oligonucleotide is a short, chemically armoured strand that pairs with one RNA. Depending on its design it either recruits an enzyme that cuts the RNA, so less protein is made, or it just sits on the RNA and changes how it is spliced, so a different protein is made. It is chosen by sequence, injected, and lasts for months.
His guess: it acts at the RNA level. His words: "Antisense oligos, which I guess intervene at the RNA level."
Checking the guess against the evidence. Correct, and the sources add a refinement. An antisense oligonucleotide acts on RNA by base-pairing with it, as the FDA label for nusinersen and the oligonucleotide chemistry review describe. But "at the RNA level" covers two quite different actions: destroying the RNA (a gapmer, via the enzyme RNase H) or only blocking a site so splicing changes (a steric blocker such as nusinersen). The same sequence logic can lower a protein or switch on a different version of it.
-
CAR T cell therapyCAR T cell therapy is a patient's own T cells, given a receptor gene outside the body and returned by infusion, to attack cells that carry one chosen surface protein. partly written
CAR T in one breath. A patient's own T cells get a gene for a receptor aimed at one surface protein, are multiplied outside the body and returned by drip. They kill cells carrying that protein, and they keep dividing, so it is a living drug. In a trial of 75 young patients with relapsed leukemia, 81% went into remission within three months.
His first guess: what CAR T is. He said: "CAR T therapy, which I'm not sure what that does. I think that's for cancers, but it eats those cells by engineering the T cells to go after the right cells."
His second question. He asked: "For CAR T cells, how do you inject them into the body so that your body doesn't reject those CAR T cells that it considers foreign?"
-
Gene therapyA medicine whose active ingredient is a gene, usually carried into cells by an emptied-out virus, so that the cell itself makes the protein. partly written
What it is, in brief. A gene therapy supplies the instruction for a protein, not the protein. The instruction travels in a hollowed-out virus, goes to chosen cells and is made there, for as long as the DNA stays. Three choices decide the outcome: the capsid and route (which cells), the vector type (how long), and the promoter and enhancer (how much and where).
Amit's guess about persistence and promoters. He said: "if it's gene therapy, then you have this sort of persistence, and you want to engineer the expression levels. Now you have to get into how often the promoter is expressed and whether you have to co-express other things so that you're able to regulate this".
-
mRNA medicines and vaccinesAn mRNA medicine is a message that cells read to make a protein for a short time; it needs a lipid carrier to enter cells. partly written
The short version. An mRNA vaccine is a temporary recipe for one protein carried in fat particles. Cells read it, make the antigen and the mRNA is then broken down. Comirnaty reached 95 percent efficacy (8 versus 162 cases); CVnCoV, 48.2 percent (83 versus 145).
-
siRNAAn siRNA is a short double-stranded RNA that guides the cell's own machinery to cut one chosen messenger RNA, so the protein is not made; it acts on RNA, not on the protein or the gene. partly written
In one paragraph. An siRNA is a short RNA duplex that makes the cell cut one chosen messenger RNA, so the protein is never built. The drug supplies a sequence; the cell's own enzyme does the cutting and is reused, so one dose can act for weeks to months. Everything hard is delivery. Patisiran slowed nerve disease; revusiran, aimed at the same target, was stopped after excess deaths.
-
Stem cell therapyStem cell therapy puts living cells into a person to replace or rebuild a tissue; the hard parts are placing them, keeping them alive and not having them rejected. partly written
The short version. Replacing cells is the goal, not the method. The cells have to reach the right place, stay and work, and not be destroyed by the recipient's immune system. Own cells avoid rejection; donor cells need immune-suppressing drugs or a genetic edit. Surviving is not enough: fetal brain grafts survived and still failed.
Is it surgery with a knife?. Sometimes, and often not. Brain tissue went in by neurosurgery through a hole in the skull; Holoclar is placed on the eye by a surgeon; but donor islets go through a catheter into a liver vein, and cord blood stem cells by drip. In none of these is the old tissue cut out and swapped back.
What Amit said and asked about it. He said: "Stem cell therapy, which just replaces the cells." He asked: "How do you replace those cells, actually? Is it just a surgery where you just literally go in with a knife, cut things out, and put them back in? How do you glue it in there so it sticks?"
-
Therapeutic monoclonal antibodiesA therapeutic antibody is a large engineered protein that binds one target outside the cell; the same modality gave a survival gain in breast cancer and a cytokine storm in six volunteers. partly written
The short version. An antibody drug is a large protein, roughly 148 kDa for trastuzumab, that binds the outside of one target. It cannot enter cells, so it works on receptors and signals. Trastuzumab lengthened survival; TGN1412 put six volunteers into cytokine storm.